EcoDrugPlus

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSCHAG00000016315
Gene Symbol: HTR1B
3 Cross references
178 Possible Orthologues:

5-Hydroxytryptamine Receptor 1e

Ensembl ID : ENSCHAG00000007972
Gene Symbol: HTR1E
3 Cross references
143 Possible Orthologues:

5-Hydroxytryptamine Receptor 1f

Ensembl ID : ENSCHAG00000010071
Gene Symbol: HTR1F
3 Cross references
140 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSCHAG00000008127
Gene Symbol: HTR2A
3 Cross references
206 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSCHAG00000022392
Gene Symbol: HTR3A
1 Cross references
205 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSCHAG00000008293
Gene Symbol: HTR3B
1 Cross references
175 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSCHAG00000013996
Gene Symbol: HTR4
1 Cross references
200 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSCHAG00000013829
Gene Symbol: HTR4
1 Cross references
200 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSCHAG00000017032
Gene Symbol: HTR7
3 Cross references
195 Possible Orthologues:

60s Ribosomal Protein L10

Ensembl ID : ENSCHAG00000010458
Gene Symbol: LOC105890639
3 Cross references
408 Possible Orthologues:

60s Ribosomal Protein L13

Ensembl ID : ENSCHAG00000014439
Gene Symbol: LOC105891117
3 Cross references
261 Possible Orthologues:

60s Ribosomal Protein L30

Ensembl ID : ENSCHAG00000019698
Gene Symbol: LOC105895124
3 Cross references
304 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).